CTLA4 and cancer: ICIs, including programmed death protein receptor-1 (PD-1), programmed death ligand-1 (PD-L1), and CTLA-4 inhibitors, are monoclonal antibodies used for the treatment of various malignancies across different clinical settings and have significantly improved the cancer-related outcomes [3].